2nd International Symposium on
Biology, Prevention, and Treatment
of Toxicities After Transplantation
and Cellular Therapy

OCTOBER 11-12, 2019
ZUCKERMAN RESEARCH CENTER
NEW YORK, NY

Memorial Sloan Kettering Cancer Center presents:
Today, more than 10,000 hematopoietic cell transplantations (HCTs) are performed yearly in the United States as treatment for more than 70 life threatening illnesses including cancers, genetic disorders, and other diseases. Also, given the shift toward cellular therapies in the field of HCT, the number of patients treated with these novel biologic agents is rapidly increasing.

Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, pharmacists, data managers, and other healthcare professionals who provide care for patients undergoing HCT and cellular therapies.

**Educational Objectives**

- Understand the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Identify best practices to prevent and treat toxicities and symptom burden after HCT and cellular therapy to improve the patient experience and reduce non-relapse mortality.
- Understand how to approach prevention and treatment of toxicities and symptom burden in unique HCT and cellular therapy patient populations.

**Call for Abstracts**

Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted. Top awarded abstracts will receive a travel grant tied to attending this symposium.

**Submission Deadline: September 14, 2019**

**Live Simulcast Available**

Visit mskcc.org/toxicities for more information or to register.

This symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

**Course Directors**

- Sergio A. Giralt, MD  
  Memorial Sloan Kettering Cancer Center
- Michael Scordo, MD  
  Memorial Sloan Kettering Cancer Center
- William A. Wood, MD  
  UNC Lineberger Comprehensive Cancer Center

**Organizing Committee**

- Miguel Perales, MD  
  Memorial Sloan Kettering Cancer Center
- Maria Cancio, MD  
  Memorial Sloan Kettering Cancer Center
- David Faleck, MD  
  Memorial Sloan Kettering Cancer Center
- Gabriela Rondon, MD  
  MD Anderson Cancer Center
- Navneet S. Majhail, MBBS, MD, MS  
  Cleveland Clinic
- Bipin N. Savani, MD  
  Vanderbilt-Ingram Cancer Center
- Shernan Holtan, MD  
  University of Minnesota
- Kenneth R. Cooke, MD  
  Johns Hopkins Sidney Kimmel Cancer Center
- Minoo Battiwalla, MD, MS  
  Sarah Cannon Center for Blood Cancer

Endothelial cells cover image credit: Kandasamy, Biomedical Microscopy Core, Paul D. Coverdell Center
### FACULTY

#### Invited Course Faculty

**Keynote Speaker**
- Andrea Bacigalupo, MD  
  Polyclinico A. Gemelli  
  Rome, Italy

**Department of Medicine Grand Rounds Lecturer**
- George McDonald, MD  
  Fred Hutchinson Cancer Research Center

**Rajni Agarwal-Hashmi, MD**  
Stanford

**Andrew Artz, MD, MS**  
UChicago Medicine

**Ami Bhatt, MD, PhD**  
Stanford

**Sita Bhella, ME, MD**  
Kingston General Hospital

**Kira Bona, MD, MPH**  
Dana Farber/Boston Children's

**Chris Bredeson, MD, MSc, FRCP**  
Ottawa Hospital Research Institute  
Ottawa, ON, Canada

**Mitchell Cairo, MD**  
New York Medical College

**Louis Cohen, MD**  
Mi Sinai

**Christopher Dandoy, MD, MS**  
Cincinnati Children’s Hospital Medical Center

**Christine Duncan, MD**  
Dana Farber/Boston Children’s

**Areej R. El-Jawahri, MD**  
Massachusetts General Hospital

**Mareike Frick, MD**  
Charite UMC  
Berlin, Germany

**MSK Course Faculty**
- Peter Bach, MD, MAPP
- JJ Boelens, MD, PhD
- Christian Otto, MD, MMSc, DABFM
- Jessica Scott, PhD

### SCHEDULE

#### DAY 1 - FRIDAY, OCTOBER 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>7:50 AM</td>
<td>Welcome, Opening Remarks and Conference Overview</td>
</tr>
<tr>
<td></td>
<td>Sergio A. Giralt, MD</td>
</tr>
<tr>
<td></td>
<td>Michael Scordo, MD</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>GI and Hepatobiliary Complications of HCT</td>
</tr>
<tr>
<td></td>
<td>George McDonald, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parental?</td>
</tr>
<tr>
<td></td>
<td>Kerry K. McMillen, MS, RD, CSO, FAND</td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury</td>
</tr>
<tr>
<td></td>
<td>Pavan Reddy, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Mechanisms of Gastrointestinal Injury in HCT – Learning from IBD</td>
</tr>
<tr>
<td></td>
<td>Louis Cohen, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Q&amp;A with Speakers</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Accelerated Functional Aging and Sarcopenia After HCT</td>
</tr>
<tr>
<td></td>
<td>Jessica M. Scott, MD</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Association of the Pulmonary Viromia and Post-HCT Pulmonary Toxicsity</td>
</tr>
<tr>
<td></td>
<td>Caroline Lindemans, MD, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapie</td>
</tr>
<tr>
<td></td>
<td>Stefan Nierkens, PhD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicsities</td>
</tr>
<tr>
<td></td>
<td>Mareike Frick, MD</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Harmonizing Conditioning Regimens – How PK/PD Impacts Toxicsities and Outcomes</td>
</tr>
<tr>
<td></td>
<td>JJ Boelens, MD, PhD</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Q&amp;A with Speakers</td>
</tr>
</tbody>
</table>

**Lunch Breakout Seminars**

**12:45 PM**  
Harnessing Biotech Innovations and Telemecine Potential in HCT and Cellular Therapies

**MODERATORS:**  
William A. Wood, MD  
Michael Scordo, MD

**SPEAKERS:**  
Chris Bredeson, MD, MSc, FRCP  
Christian Otto, MD, MMSc, DABFM

**Using Dynamic Scoring Systems to Predict and Prevent NRM After HCT**

**MODERATORS:**  
Miguel Perales, MD  
Sergio A. Giralt, MD

**SPEAKERS:**  
Thomas Luft, MD, PhD  
Andrea Bacigalupo, MD
### Day 2 - Saturday, October 12

#### 7:30 AM  |  Breakfast

#### Morning Seminar/Debate

**Moderators:** Hillard Lazarus, MD, FACP and Kenneth R. Cooke, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Harmonizing VOD/SOS Diagnosis and Classification</td>
<td>Mitchell Cairo, MD, Richard J. Jones, MD, George McDonald, MD</td>
</tr>
</tbody>
</table>

#### Keynote Address

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:50 AM</td>
<td>Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy</td>
<td>Bronwen E. Shaw, MD, PhD</td>
</tr>
</tbody>
</table>

#### Investigational Research in Toxicities – From Bench to Bedside

**Moderators:** Navneet S. Majhail, MBBS, MD, MS and Bipin N. Savani, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:35 AM</td>
<td>Use of Non-Genotoxic Conditioning to Mitigate Regimen-Related Toxicity</td>
<td>Rajni Agarwal-Hashmi, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>The Injured Endothelium in HCT Toxicities</td>
<td>Christopher Dandoy, MD, MS</td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Virus specific T cells to Mitigate Infectious Complications After HCT</td>
<td>Pawel Muranski, MD</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:05 AM</td>
<td>Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies</td>
<td>Ami Bhatt, MD, PhD</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies</td>
<td>Benjamin Laskin, MD, MS</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design</td>
<td>Sherman Holtan, MD</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Q&amp;A with Speakers</td>
<td></td>
</tr>
</tbody>
</table>

#### Keynote Address

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 PM</td>
<td>Preventing All-Cause Death after HCT - What Should be our Focus when Designing Trials?</td>
<td>Andrea Bacigalupo, MD</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Symposium Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
REGISTRATION

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Category</th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, PharmDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Advanced Practice Providers, Nurses, Data Managers and Other Healthcare Providers</td>
<td>$200</td>
<td>$250</td>
</tr>
<tr>
<td>Residents, Fellows</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
<tr>
<td>Live Simulcast</td>
<td>--</td>
<td>$600</td>
</tr>
</tbody>
</table>

*Early registration rates available through August 31, 2019.
**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

REGISTER ONLINE:

mskcc.org/toxicities

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

Location & Accommodations

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: mskcc.org/cme

IN COLLABORATION WITH

UNC Lineberger Comprehensive Cancer Center
American Society for Transplantation and Cellular Therapy (ASTCT)
MD Anderson Cancer Center
Cleveland Clinic
Vanderbilt-Ingram Cancer Center
University of Minnesota
Sarah Cannon Center for Blood Cancer
Johns Hopkins Sidney Kimmel Cancer Center

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

MSK designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.